홈
탐색
nav.journalClub
트렌드
더보기
synapse
⌘+K
언어
한국어
한국어
T-allo10 Cell Addback Post-Αβdepleted-HSCT Drives Lasting Leukemia-Free Survival with Distinct Immune Regulation Biomarkers | Synapse
March 3, 2026
T-allo10 Cell Addback Post-Αβdepleted-HSCT Drives Lasting Leukemia-Free Survival with Distinct Immune Regulation Biomarkers
AB
Alice Bertaina
RB
Rosa Bacchetta
Lucile Packard Children's Hospital
DS
David C. Shyr
Lucile Packard Children's Hospital
See all
Key Points
Leukemia-free survival improves significantly with T-allo10 cell addback after abdepleted-hsct.
The analysis shows a marked increase in lasting leukemia-free survival reaching 80% at one year.
Assessment using immune regulation biomarkers reveals distinct profiles after T-allo10 treatment.
Implications suggest novel therapeutic strategies may enhance outcomes in leukemia treatment.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Bertaina et al. (Sun,) studied this question.
synapsesocial.com/papers/69a760adc6e9836116a2da9f
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.145
Mark Helpful
Like
Save
Bookmark
Relay
Share